Newron and Myung In Pharm announce license agreement for schizophrenia in South Korea

Newron Pharmaceuticals and Myung In Pharm have partnered to develop and sell evenamide, a new treatment for treatment-resistant schizophrenia, in South Korea. Myung In Pharm will provide 10% of the patients for Newron’s Phase III trial and cover costs, with the trial starting in H1 2025 and overseen by Newron. Myung In Pharm will also […]